EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SMR Peptide Modulates Tumor-Derived Extracellular Vesicles microRNA and Inflammatory Transcript Signatures in TNBC

Ming-Bo Huang, Fengxia Yan iD, Uswa Jadoon iD, Jennifer Y Wu, Dara Brena, Erica L Johnson, Jonathan Stiles iD, Lily Yang, Brian M Rivers iD, Vincent C Bond iD

Cells · 2026

DOI: 10.3390/cells15060550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Ming-Bo Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA. Hauptthemen laut MEDLINE: MicroRNAs, Triple Negative Breast Neoplasms, Extracellular Vesicles, Peptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the American Cancer Society (ACS) Diversity in Cancer Research-Cancer Health Equity Research Institutional Development Grant Program, NIH/NIMHD, NIH NIMHD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies and characterized by pronounced heterogeneity and widespread dysregulation of microRNAs (miRNAs) that influence epithelial-to-mesenchymal transition (EMT) and metastasis. Tumor-derived extracellular vesicles (tEVs) further contribute to TNBC progression by transporting oncogenic cargo that can enhance pro-inflammatory signaling. The synthetic SMRwt peptide has been suggested to modulate oncogenic pathways; however, its effects on EV miRNA composition and inflammatory transcript profiles in TNBC remain unclear. Here, we investigated whether SMRwt alters tEV-associated miRNAs and cytokine transcript signatures relevant to EMT and inflammasome-linked pathways. Extracellular vesicles were isolated from SMR-treated and untreated MDA-MB-231 cells, followed by nanoparticle tracking analysis and small RNA sequencing. SMRwt treatment enriched 11 tumor-suppressive miRNAs (including Let-7a-5p, Let-7b-5p, miR-24-3p, miR-26b-5p, miR-92a-3p, miR-93-5p, and miR-496) previously associated with the regulation of proliferation, EMT, migration, and metastasis. We also observed modest, non-significant decreases (1.01–1.27-fold) in oncogenic miR-1200, miR-374a-5p, and miR-937-3p, which have been implicated in the progression of breast, lung, and bone malignancies. Complementary transcriptomic profiling using the NanoString nCounter Breast Cancer 360 Gene Expression Panel (NanoString Technologies, Inc., Seattle, CA, USA) demonstrated reduced expression of inflammasome-associated cytokines in TNBC cells relative to non-tumorigenic controls, including a log2 fold change of −1.15 for IL 1β (MDA-MB-231 vs. MCF10A). These transcript-level changes suggest potential modulation. Additionally, SMRwt suppresses ASC-mediated caspase-1 activation and reduces IL-1β secretion, thereby inhibiting NLRP3 inflammasome signaling. Therefore, we infer that SMRwt simultaneously restores tumor-suppressive miRNA networks and suppresses inflammasome-driven inflammation, supporting its potential as a dual-target therapeutic strategy for TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsTriple Negative Breast NeoplasmsExtracellular VesiclesPeptidesInflammationHumansMDA-MB-231 CellsFemaleGene Expression Regulation, NeoplasticInflammasomesCell Line, TumorEpithelial-Mesenchymal Transition

Stichwörter der Autor:innen

NLRP3SMR peptideTNBCapoptosis-associated speck-like protein (ASC)caspase-1exosomesextracellular vesicles (EVs)inflammasomemicroRNA (miRNA)tumor-derived EVs (tEVs)

Substanzen

MicroRNAsPeptidesInflammasomes

Autor:innen und Institutionen

  • Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA.
  • Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA.
  • School of International and Public Affairs, Columbia University, New York, NY 10027, USA.
  • Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA 30310, USA.

ORCID-Profile: Fengxia Yan, Uswa Jadoon, Jonathan Stiles, Brian M Rivers, Vincent C Bond

Förderung

  • the American Cancer Society (ACS) Diversity in Cancer Research-Cancer Health Equity Research Institutional Development Grant Program
  • NIH/NIMHD
  • NIH NIMHD
  • American Cancer Society (ACS) Diversity in Cancer Research—Cancer Health Equity Research Institutional Development Grant Program
  • National Institutes of Health

Zitieren

APA

Huang, M. B., Yan, F., Jadoon, U., Wu, J. Y., Brena, D., Johnson, E. L., Stiles, J., Yang, L., Rivers, B. M., & Bond, V. C. (2026). SMR Peptide Modulates Tumor-Derived Extracellular Vesicles microRNA and Inflammatory Transcript Signatures in TNBC. Cells. https://doi.org/10.3390/cells15060550

Vancouver

Huang MB, Yan F, Jadoon U, Wu JY, Brena D, Johnson EL, et al. SMR Peptide Modulates Tumor-Derived Extracellular Vesicles microRNA and Inflammatory Transcript Signatures in TNBC. Cells. 2026. doi:10.3390/cells15060550

BibTeX
@article{Huang2026,
  author = {Huang, Ming-Bo and Yan, Fengxia and Jadoon, Uswa and Wu, Jennifer Y and Brena, Dara and Johnson, Erica L and Stiles, Jonathan and Yang, Lily and Rivers, Brian M and Bond, Vincent C},
  title = {SMR Peptide Modulates Tumor-Derived Extracellular Vesicles microRNA and Inflammatory Transcript Signatures in TNBC},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15060550}
}
Kostenlos starten →